GlassScriptPhysician profile
Deadra Jordan
NPI 1366052805
$878.41
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.29 · 2022: $389 · 2023: $378 · 2024: $49.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $178.76 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $137.56 | 2022-2024 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.85 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $116.81 | 2021-2023 | Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $45.91 | 2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $45.61 | 2022 | |
| Lundbeck LLC | $37.35 | 2022-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $28.63 | 2022 | |
| Tris Pharma INC | $27.99 | 2021-2023 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $27.48 | 2024 | Rexulti |
| Alkermes, INC. | $24.42 | 2022 | |
| Indivior INC. | $22.18 | 2023 | Perseris |
| Bausch Health US, LLC | $21.16 | 2023 | Wellbutrin, Aplenzin |
| Eisai INC. | $20.27 | 2021 | |
| Merck Sharp & Dohme LLC | $16.43 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deadra Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.